Time is prognosis: Early treatment of HF in both acute and chronic settings
Heart failure is often underrecognized despite early warning signs. Delays in diagnosis and appropriate treatment can significantly worsen prognosis.1 By the time a patient is hospitalized for HF, the risk of rehospitalization and mortality has greatly increased. In this webinar, Professor Javed Butler from the University of Mississippi, United States, discussed data on the use of empagliflozin in HF patients, highlighting the benefits of early initiation in both chronic and acute settings as reflected by the latest guidelines. He also emphasized that medications such as sodium-glucose cotransporter 2 inhibitors exert a comprehensive impact across diverse cardio-renal-metabolic (CRM) conditions due to their direct and indirect actions, which collectively offer risk reduction across these interconnected disease states.
This is an independent editorial material, published and distributed through unrestricted educational support from the pharmaceutical community, for the purpose of continuing medical education only. The views expressed in this publication reflect the experience and/or opinion of the author(s) and are not necessarily those of editors, publisher, and sponsor(s). Because of rapid advances in medicine, independent verification of clinical diagnoses, medical suitability and dosage should be made before treatment prescription. The appearance of advertisement, if any, has no influence on editorial content or presentation and does not imply the endorsement of products by the publication, or its authors and editors.
